NEW YORK, May 23 (Reuters) - Allergan Plc Chief
Executive Brent Saunders said on Monday the company expects to
close the $40.5 billion sale of its generic medicines portfolio
to Teva Pharmaceutical Industries Ltd in a matter of
weeks, opening the door for new acquisitions.
Read more
No comments:
Post a Comment